Healthcare / Ironwood Pharmaceuticals: LINZESS Fuels Profitable Growth Blowout earnings and raised guidance. Ironwood Pharmaceuticals ($IRWD) is dominating the GI market with LINZESS sales up 40% YoY. We analyze why this profitable biotech is a buy despite pipeline delays. By Marques Blank / 8 Jan 2026
